Aptose Biosciences’ TUSCANY Study Highlighted at ASH 2025

Aptose Biosciences ( (TSE:APS) ) just unveiled an update.

On November 3, 2025, Aptose Biosciences announced that an abstract from its TUSCANY study, which investigates the combination of tuspetinib with standard care drugs venetoclax and azacitidine for newly diagnosed AML patients, has been selected for a poster presentation at the 2025 ASH Annual Meeting. This selection highlights the potential of Aptose’s therapy in addressing unmet needs in AML treatment, potentially enhancing the company’s standing in the oncology field.

The most recent analyst rating on (TSE:APS) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.

Spark’s Take on TSE:APS Stock

According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.

Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.

To see Spark’s full report on TSE:APS stock, click here.

More about Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology. The company is advancing its lead oral kinase inhibitor, tuspetinib, as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML).

YTD Price Performance: -80.72%

Average Trading Volume: 3,050

Technical Sentiment Signal: Sell

Current Market Cap: C$4.8M

See more data about APS stock on TipRanks’ Stock Analysis page.